These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27095876)

  • 1. Time to reconsider routine high-dose amoxicillin for community-acquired pneumonia in all Canadian children.
    Rajapakse NS; Vayalumkal JV; Vanderkooi OG; Ricketson LJ; Kellner JD
    Paediatr Child Health; 2016 Mar; 21(2):65-6. PubMed ID: 27095876
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community -acquired pneumonia in children.
    Aurangzeb B; Hameed A
    J Coll Physicians Surg Pak; 2003 Dec; 13(12):704-7. PubMed ID: 15569557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review.
    Mathur S; Fuchs A; Bielicki J; Van Den Anker J; Sharland M
    Paediatr Int Child Health; 2018 Nov; 38(sup1):S66-S75. PubMed ID: 29790844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis.
    Lorgelly PK; Atkinson M; Lakhanpaul M; Smyth AR; Vyas H; Weston V; Stephenson T
    Eur Respir J; 2010 Apr; 35(4):858-64. PubMed ID: 19717479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial.
    Llor C; Pérez A; Carandell E; García-Sangenís A; Rezola J; Llorente M; Gestoso S; Bobé F; Román-Rodríguez M; Cots JM; Hernández S; Cortés J; Miravitlles M; Morros R
    Aten Primaria; 2019 Jan; 51(1):32-39. PubMed ID: 29061311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group.
    Aubier M; Verster R; Regamey C; Geslin P; Vercken JB
    Clin Infect Dis; 1998 Jun; 26(6):1312-20. PubMed ID: 9636854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
    Petitpretz P; Arvis P; Marel M; Moita J; Urueta J;
    Chest; 2001 Jan; 119(1):185-95. PubMed ID: 11157603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days.
    Paris R; Confalonieri M; Dal Negro R; Ligia GP; Mos L; Todisco T; Rastelli V; Perna G; Cepparulo M
    J Chemother; 2008 Feb; 20(1):77-86. PubMed ID: 18343748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
    File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community-Acquired Pneumonia in Children.
    Leung AKC; Wong AHC; Hon KL
    Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):136-144. PubMed ID: 29932038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of amoxicillin-clavulanic acid 1000/125mg twice daily extended release (XR) tablet for the treatment of bacterial community-acquired pneumonia in adults.
    Prabhudesai PP; Jain S; Keshvani A; Kulkarni KP
    J Indian Med Assoc; 2011 Feb; 109(2):124-7. PubMed ID: 21888181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of childhood complicated community-acquired pneumonia with amoxicillin/sulbactam.
    Lovera D; Arbo A
    J Chemother; 2005 Jun; 17(3):283-8. PubMed ID: 16038522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of National Guidelines on the Management of Community-Acquired Pneumonia in Children. Do Pediatricians Follow the Recommendations?
    Kraj G; Peradzyńska J; Chądzyńska J; Kulus M; Wołoszyn K; Jackowska T; Krajewska M; Mołdoch-Łukasik A; Czubik-Przybyła A; Górska-Kot A; Krenke K
    Adv Exp Med Biol; 2019; 1211():103-110. PubMed ID: 31144241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penicillin G/ofloxacin versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia.
    Gaillat J; Bru JP; Sedallian A
    Eur J Clin Microbiol Infect Dis; 1994 Aug; 13(8):639-44. PubMed ID: 7813493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia.
    Hagberg L; Torres A; van Rensburg D; Leroy B; Rangaraju M; Ruuth E
    Infection; 2002 Dec; 30(6):378-86. PubMed ID: 12478329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are third-generation cephalosporins associated with a better prognosis than amoxicillin-clavulanate in patients hospitalized in the medical ward for community-onset pneumonia?
    Batard E; Javaudin F; Kervagoret E; Caruana E; Le Bastard Q; Chapelet G; Goffinet N; Montassier E
    Clin Microbiol Infect; 2018 Nov; 24(11):1171-1176. PubMed ID: 29964229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study.
    el Moussaoui R; de Borgie CA; van den Broek P; Hustinx WN; Bresser P; van den Berk GE; Poley JW; van den Berg B; Krouwels FH; Bonten MJ; Weenink C; Bossuyt PM; Speelman P; Opmeer BC; Prins JM
    BMJ; 2006 Jun; 332(7554):1355. PubMed ID: 16763247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia.
    Benninger MS
    Expert Opin Pharmacother; 2003 Oct; 4(10):1839-46. PubMed ID: 14521493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group.
    Mandell LA; Marrie TJ; Grossman RF; Chow AW; Hyland RH
    Clin Infect Dis; 2000 Aug; 31(2):383-421. PubMed ID: 10987698
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.